draft resolution of the pharmacopoeial monographs on the heparin sodium from bovine and porcine in the brazilian pharmacopoeia draft resolution of the pharmacopoeial monographs on the heparin sodium from bovine and porcine in the brazilian pharmacopoeia. the heparin sodium from bovine is extracted from the bovine intestine and contains a mix of polysaccharide chains with different molecular weight. it is composed of units of 61537 -d-glucosamine and acid 61537 61485 iduronic 2-sulfated. the units of 61537 -d-glucosamine present a more heterogeneous pattern of sulphatation in comparison with the heparin from porcine. in special we observe higher proportion of units of 61537 -d-glucosamine non-sulphated in the position 6. it has anticoagulant activity by the inhibition of many factors of the coagulation system prolonging the time of coagulation in blood. this occurs mainly through potentiation of the xa factor inactivation and of the thrombin through the antithrombin. it contains at least 160 units of anti-factor lla activity for mg of heparin respectively in relation to desiccated substance. the reason of the anti-factor xa activity for the anti-factor lla activity must be of 1.0 0.1. the animals from which the heparin is extracted must fulfil the sanitary requirements of the species and the manufacturing process must ensure the elimination or the inactivation of infectious agents. the heparin sodium from porcine is extracted from the intestine of the porcine and contains a mix of polysaccharide chains with different molecular weight. it is composed preponderantly for alternated units of 61537 -d-glucosamine n- and 6- disulfated and acid 61537 61485 iduronic 2-sulfated. it has anticoagulant activity due to the inhibition of many factors of the coagulation system prolonging the time of coagulation in blood. this occurs mainly through potentiation of the xa factor inactivation and of the thrombin through the antithrombin. it contains at least 180 units of anti-factor lla activity for mg of heparin in relation to desiccated substance. the reason of the anti-factor xa activity for the anti-factor lla activity must be 1.0 0.1. the animals from which the heparin is extracted must fulfil the sanitary requirements of the species in question and the manufacturing process must ensure the elimination or the inactivation of infectious agents. these monograph proposals set standards for the identity dosage according to methods anti-factor xa activity and anti-factor iia activity ion-exchange high-performance liquid chromatography technique for detection and separation of possible contaminants of the heparin characteristics purity assays biological safety tests packaging storing and labeling of the heparin sodium from bovine and porcine in the brazilian pharmacopoeia